113 related articles for article (PubMed ID: 36271518)
1. Expression of concern: miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1 [Biomedicine & Pharmacotherapy 106 (2018) 1072-1081].
Biomed Pharmacother; 2022 Nov; 155():113813. PubMed ID: 36271518
[No Abstract] [Full Text] [Related]
2. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
3. Retraction notice to "miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1" [Biomed. Pharmacother. 106 (2018) 1072-1081].
Deng H; Geng Q; Ji T; Yang A
Biomed Pharmacother; 2023 Jun; 162():114720. PubMed ID: 37087344
[No Abstract] [Full Text] [Related]
4. RETRACTED: miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Long Non-Coding RNA
Zhan Y; Abuduwaili K; Wang X; Shen Y; Nuerlan S; Liu C
Cancer Manag Res; 2020; 12():7725-7737. PubMed ID: 32943921
[TBL] [Abstract][Full Text] [Related]
6. DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4.
Panneerselvam J; Mohandoss P; Patel R; Gillan H; Li M; Kumar K; Nguyen D; Weygant N; Qu D; Pitts K; Lightfoot S; Rao C; Houchen C; Bronze M; Chandrakesan P
Mol Ther Oncolytics; 2020 Sep; 18():24-36. PubMed ID: 32637578
[TBL] [Abstract][Full Text] [Related]
7. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
[TBL] [Abstract][Full Text] [Related]
9. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
[TBL] [Abstract][Full Text] [Related]
10. DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.
Zhang L; Zhou S; Guo E; Chen X; Yang J; Li X
Pflugers Arch; 2020 Aug; 472(8):1041-1049. PubMed ID: 32533239
[TBL] [Abstract][Full Text] [Related]
11. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
12. Silencing of miR-19a-3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN.
Zhang B; Liu Y; Zhang J
Oncol Lett; 2019 Jan; 17(1):414-421. PubMed ID: 30655782
[TBL] [Abstract][Full Text] [Related]
13. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
14. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC.
Wang X; Chen X; Meng Q; Jing H; Lu H; Yang Y; Cai L; Zhao Y
Sci Rep; 2015 Dec; 5():17618. PubMed ID: 26620926
[TBL] [Abstract][Full Text] [Related]
15. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1.
Sakaguchi M; Hisamori S; Oshima N; Sato F; Shimono Y; Sakai Y
Mol Cancer Res; 2016 Apr; 14(4):354-62. PubMed ID: 26747706
[TBL] [Abstract][Full Text] [Related]
16.
Chen C; Zhou Y; Ding P; He L
Genet Test Mol Biomarkers; 2021 Aug; 25(8):540-545. PubMed ID: 34406846
[No Abstract] [Full Text] [Related]
17. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
Pei K; Zhu JJ; Wang CE; Xie QL; Guo JY
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4697-4704. PubMed ID: 27906433
[TBL] [Abstract][Full Text] [Related]
19. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
[TBL] [Abstract][Full Text] [Related]
20. miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein.
Zhu X; Li D; Yu F; Jia C; Xie J; Ma Y; Fan S; Cai H; Luo Q; Lv Z; Fan L
Oncotarget; 2016 Mar; 7(11):13139-52. PubMed ID: 26909612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
